Verweise von und zu Tumor therapeutics, antineoplastic
Zurück zum ArtikelVerweise zu anderen Artikeln
- Abarelix
- Abc transporters
- Abiraterone
- Alemtuzumab
- Alkylants
- Anastrozole
- Androgen receptor antagonists
- Antimetabolites
- Apalutamide
- Aromatase inhibitors
- Bevacizumab
- Bicalutamide
- Bleomycin
- Buserelin
- Cabazitaxel
- Capecitabine
- Carboplatinum
- Carmustin
- Cetuximab
- Chlorambucil
- Cisplatin
- Cyclophosphamide
- Dasatinib
- Daunorubicin, liposomal
- Degarelix
- Docetaxel
- Doxorubicin
- Egf receptors
- Erlotinib
- Etoposide
- Copy
- Fluorouracil
- Flutamid
- Folic acid analogues
- Gemcitabine
- Gonadorelin receptor agonists
- Gonadorelin receptor antagonists
- Hydroxycarbamide
- Ifosfamide
- Imatinib
- Irinotecan
- KIT gene
- Letrozole
- Lomustin
- Melphalan
- Mitosis inhibitors
- Monoclonal antibodies
- Mtor
- Nilotinib
- Nitrosourea
- Nivolumab
- Oxaliplatin
- P53 protein
- Paclitaxel
- Panitumumab
- Pdgfr inhibitors of the small molecule immuno-oncology agent type
- Pemetrexed
- Pentostatin
- Pertuzumab
- Platinum analogues
- Protooncogenes
- Pyrimidine analogues
- Raf-kinasen
- Rituximab
- Selective estrogen receptor modulators
- Sorafenib
- Nitrogen lost derivatives
- Sunitinib
- Tamoxifen
- Taxanes
- Temozolomide
- Teniposide
- Thiotepa
- Topoisomerase inhibitors
- Topotecan
- Trastuzumab
- Triptorelin
- Trofosfamide
- Tumor suppressor genes
- Tyrosine kinase inhibitors
- Vegf
- VEGFR inhibitors
- Vemurafenib
- Vinblastine
- Vincrist
- Growth factors